Intervalo de tempo entre o rastreio citológico e o seguimento das mulheres com lesões precursoras do câncer da cérvice uterina, em Campo Grande-MS, 2014 - 2018

Abstract

Cervical cancer is the fourth most common type of cancer among women. Screening contributes to the early diagnosis of precursor lesions, allowing treatment at a stage of the disease where there is a possibility of up to 100% cure, justifying population screening in women. Nearly half of women with cervical cancer have never been screened and another 10% have not been screened in the five years prior to diagnosis. The WHO recommendation is that 80% of women between 25 and 64 years old have a Pap test every three years. The objective of the research was to identify the time interval between cytological screening, interpretation of cytology results and the beginning of the follow-up of women with cervical cancer precursor lesions, screened in municipal Health Units on an outpatient basis. A quantitative, retrospective, cross-sectional research was carried out in the city of Campo Grande/MS, from January 2014 to December 2018, which included secondary data of altered results of cytology collected in women over 25 years of age. Next, data from SISCAN (Cancer Information System) were crossed with information stored in HYGIA (computer system used by the municipality of Campo Grande) using the Microsoft® Excel program (MICROSOFT Corporation, 2013). Of the total of 3488 exams collected, 39.47% of the women who presented altered results attended a medical nursing consultation and 60.53% did not have the interpretation of their exams. Regardless of the cytology result, we observed that the majority, 1014 (73.64%) made the consultation after the cytology collection in a time interval greater than 300 days. The results found suggest that the role of cervical screening is not being properly achieved. The follow-up of women with altered cytology should go through a process of constant and continuous active search to allow the criteria of the brazilian guidelines for the prevention of uterine cancer to be put into practice.